Activity of AFN-1252, a novel FabI inhibitor, against Staphylococcus aureus in an in vitro pharmacodynamic model simulating human pharmacokinetics

Journal of Chemotherapy

Volumn 25, Issue 1, 2013, Pages 32-35

  Tsuji, Brian T ^a   Harigaya, Yoriko ^a,b   Lesse, Alan J ^c   Forrest, Alan ^a   Ngo, Dung ^a  

^a UNIVERSITY AT BUFFALO   (United States)

^b CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

^c UNIVERSITY AT BUFFALO   (United States)

Author keywords

AFN 1252; Bactericidal; FabI; MRSA; MSSA; Pharmacodynamics; Staphylococccus aureus

Indexed keywords

AFN 1252; ENZYME INHIBITOR; UNCLASSIFIED DRUG;

ANTIBIOTIC SENSITIVITY; AREA UNDER THE CURVE; ARTICLE; BACTERIAL STRAIN; BACTERIAL VIABILITY; IN VITRO STUDY; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; METHICILLIN SUSCEPTIBLE STAPHYLOCOCCUS AUREUS; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PHARMACODYNAMICS; SIMULATION; STAPHYLOCOCCUS INFECTION;

ANTI-BACTERIAL AGENTS; BENZOFURANS; HUMANS; METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS; MICROBIAL SENSITIVITY TESTS; MODELS, BIOLOGICAL; PYRONES; STAPHYLOCOCCAL INFECTIONS; STAPHYLOCOCCUS AUREUS;

EID: 84873152696     PISSN: 1120009X     EISSN: 19739478     Source Type: Journal    
DOI: 10.1179/1973947812Y.0000000060     Document Type: Article

References (15)

1. Heath RJ, Rock CO. Fatty acid biosynthesis as a target for novel antibacterials. Curr Opin Investig Drugs. 2004;5:146-53.
2. Karlowsky JA, Laing NM, Baudry T, Kaplan N, Vaughan D, Hoban DJ, et al. In vitro activity of API-1252, a novel FabI inhibitor, against clinical isolates of Staphylococcus aureus and Staphylococcus epidermidis. Antimicrob Agents Chemother. 2007;51:1580-1.
3. Kaplan N, Yethon J, Albert M, Bardouniotis E, Thalakada R, Walsh N, et al. In vitro characterization of API-1252, a novel inhibitor of bacterial fatty acid biosynthesis, against drug resistant staphylococci. Proceedings of the 46th Interscience Conference on Antimicrobial Agents and Chemotherapy; 2006 Sep 27-30; San Francisco, CA, USA. Poster F1-0754.
4. Kaplan N, Albert M, Awrey D, Bardouniotis E, Berman J, Clarke T, et al. AFN-1252 - mode of action, in vitro activity and in vivo efficacy of a selective anti-staphylococcal FabI inhibitor. Antimicrob Agents Chemother. 2012;56(11):5865-74.
5. Banevicius MA, Deryke CA, Kaplan N, Vaughan D, Nicolau DP. In vivo pharmacodynamic profiling of API-1252 against Staphylococcus aureus in a murine thigh model. Proceedings of the 46th Interscience Conference on Antimicrobial Agents and Chemotherapy; 2006 Sep 27-30; San Francisco, CA, USA. Poster F1-0759.
6. Weis WJ, Hafkin B, Kaplan N, Pulse M, Nguyen P, Renick P, et al. Oral pharmacokinetics and effficacy of AFN-1252 in a murine septicaemia infection model with S. aureus. Proceedings of the 50th Interscience Conference on Antimicrobial Agents and Chemotherapy; 2010 Sep 12-15; Boston, MA, USA. Poster F1-833.
7. Kaplan N, Hafkin B. Tolerability, safety and pharmacokinetics of multiple oral doses of AFN-1252 in healthy subjects. Proceedings of the 46th Interscience Conference on Antimicrobial Agents and Chemotherapy; 2006 Sep 27-30; San Francisco, CA, USA. Poster F1-1349.
8. Clinical and Laboratory Standards Institute. Performance standards for antimicrobial susceptibility testing, 15th informational supplement M100-S15. Wayne, PA: CLSI; 2005.
9. Kaplan N, Flanner H, Hafkin B. Correlation of AFN-1252 phase 0 microdosing and phase I pharmacokinetics. F1-2006. Proceedings of the 49th Interscience Conference on Antimicrobial Agents and Chemotherapy; 2009 Sep 12-15; San Francisco, CA, USA. Poster F1-2009.
10. Harigaya Y, Bulitta JB, Forrest A, Sakouluas G, Lesse AJ, Mylotte JM, et al. Pharmacodynamics of vancomycin at simulated epithelial lining fluid concentrations against methicillin-resistant Staphylococcus aureus (MRSA): implications for dosing in MRSA pneumonia. Antimicrob Agents Chemother. 2009;53:3894-901.
11. Tsuji BT, von Eiff C, Kelchlin PA, Forrest A, Smith PF. Attenuated vancomycin bactericidal activity against Staphylococcus aureus hemB mutants expressing the small-colony-variant phenotype. Antimicrob Agents Chemother. 2008;52:1533-7.
12. Clinical and Laboratory Standards Institute. Methods for determining bactericidal activity of antimicrobial agents; approved guideline M26A. Wayne, PA: CLSI; 1999.
13. Park HS, Yoon YM, Jung SJ, Kim CM, Kim JM, Kwak JH. Antistaphylococcal activities of CG400549, a new bacterial enoyl-acyl carrier protein reductase (FabI) inhibitor. J Antimicrob Chemother. 2007;60:568-9.
14. Escaich S, Prouvensier L, Saccomani M, Durant L, Oxoby M, Gerusz V, et al. The MUR056399 inhibitor of FabI is a new antistaphylococcal compound. Antimicrob Agents Chemother. 2011;55:4692-7.
15. Banevicius MA, Deryke CA, Kaplan N, Vaughan D, Nicolau DP. In vivo pharmacodynamic profiling of API-1252 against Staphylococcus aureus in a murine thigh model. Proceedings of the 46th Interscience Conference on Antimicrobial Agents and Chemotherapy; 2006 Sep 27-30; San Francisco, CA, USA. Poster F1-0759.